Skip to main content

Table 1 Clinical characteristics of low EPC (CD133/Flk1+  < 0.0881%) and high EPC (CD133/Flk1+  > 0.0881%) groups

From: Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients

  All patients (n = 101) Low EPC group (n = 51) High EPC group (n = 50) P value
Demographics     
Age, years 66.96 (10.6) 69.5 (8.8) 64.4 (11.7) 0.014
Male sex (%) 69.3 68.6 70 0.881
HD vintage (years) 5.91 (2.08–12.29) 6.56 (3.26–11.58) 5.00 (1.12–13.4) 0.166
Inpatients (%) 93.1 98.0 88.0 0.047
BMI (kg/m2) 22.04 (3.94) 22.16 (4.53) 21.93 (3.27) 0.769
Clinical measurements     
Albumin (g/dL) 2.98 (0.49) 2.90 (0.49) 3.06 (0.48) 0.094
BUN (mg/dL) 43.8 (16.0) 43.8 (15.1) 43.7 (16.9) 0.979
Creatinine (mg/dL) 8.19 (2.02) 7.93 (1.91) 8.44 (2.12) 0.216
adjusted Ca (mg/dL) 9.58 (0.79) 9.65 (0.72) 9.49 (0.84) 0.306
Phosphate (mg/dL) 4.22 (1.45) 4.13 (1.32) 4.32 (1.57) 0.516
CRP (mg/dL) 0.86 (0.21–3.11) 1.44 (0.27–4.55) 0.63 (0.15–1.69) 0.017
WBC (/mm3) 6100 (4900–7150) 6200 (4900–7000) 6050 (4300–7225) 0.649
Hemoglobin (g/dL) 9.97 (1.59) 9.95 (1.71) 9.99 (1.47) 0.902
Serum iron (μg/dL) 40.0 (27.5–63.5) 39.0 (26.0–64.0) 40.5 (30.0–57.0) 0.831
TSAT (%) 21.7 (12.7) 21.5 (12.9) 21.8 (12.6) 0.909
Ferritin (ng/mL) 118.8 (53.4–241.2) 121.4 (62.7–245.4) 117.3 (43.1–243.4) 0.545
Glucose (mg/dL) 144.4 (49.0) 142.2 (34.5) 146.7 (60.6) 0.649
Total cholesterol (mg/dL) 150.9 (43.3) 148.0 (43.4) 153.8 (43.4) 0.503
Triglyceride (mg/dL) 100.5 (45.4) 102.2 (49.1) 98.8 (41.8) 0.709
Intact PTH (pg/mL) 117.6 (63.2–207.6) 113.8 (60.5–178.8) 124.0 (63.8–217.0) 0.386
BNP (pg/mL) 338.7 (134.5–881.8) 315.2 (151.0–1096) 350.1 (99.6–815.1) 0.325
SBP (mmHg) 145.0 (26.9) 140.5 (24.4) 149.6 (28.8) 0.088
DBP (mmHg) 75.0 (14.79) 72.3 (13.9) 77.7 (15.3) 0.068
Pulse rate (/min) 75.5 (13.5) 77.3 (15.0) 73.7 (11.6) 0.177
CD133/Flk1 + EPC (%) 0.0880 (0.0370–0.1615) 0.0393 (0.0264–0.0613) 0.1615 (0.1168–0.3926)  < 0.001
CD34/Flk1 + EPC (%) 0.0723 (0.0381–0.1502) 0.0397 (0.0175–0.0687) 0.1303 (0.0741–0.3755)  < 0.001
ERI (IU/week/kg/g/dL) 18.4 (7.2–33.0) 20.4 (8.0–46.7) 15.6 (6.6–29.0) 0.240
Comorbidities     
Charlson index 7.0 (6.0–9.0) 8.0 (6.0–9.0) 7.0 (6.0–9.0) 0.210
CAD (%) 23.8 29.4 18.0 0.178
CVD (%) 17.8 19.6 16.0 0.636
PVD (%) 23.8 29.4 18.0 0.178
CHF (%) 27.7 33.3 22.0 0.203
Dementia (%) 2.0 3.9 0 0.157
DM (%) 49.5 52.9 46.0 0.485
Malignancy (%) 23.8 25.5 22.0 0.680
Treatments     
ESA dose (IU/week/kg) 161.6 (75.0–320.9) 179.0 (80.4–444.4) 150.5 (71.0–285.1)  
Epoetin (%) 30.7 29.4 32.0 0.778
DA (%) 64.4 70.6 58.0 0.187
CERA (%) 5.0 0 10.0 0.021
Iron agent (%) 36.6 43.1 30.0 0.171
Vitamin D (%) 68.3 66.7 70.0 0.719
CaSR agonist (%) 32.7 35.3 30.0 0.571
  1. Continuous variables are expressed as mean (SD) or median (interquartile range). Categorical variables are expressed as percentages. P values in bold indicate statistical significance
  2. BMI, body mass index; BUN, blood urea nitrogen; Ca, calcium; CRP, C-reactive protein; WBC, white blood cell; TSAT, transferrin saturation; PTH, parathyroid hormone; BNP, brain natriuretic peptide; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; CVD, cerebral vascular disease; PVD, peripheral vascular disease; CHF, congestive heart failure; DM, diabetes mellitus; DA, darbepoetin alpha; CERA, continuous erythropoietin receptor activator; CaSR, calcium-sensing receptor